NCT06554288View on ClinicalTrials.gov

Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

November 30, 2029

Study Completion Date

December 31, 2029

Conditions
Pediatric DisorderGenetic PredispositionDystonia, SecondaryDystoniaCerebral Palsy, Dystonic-RigidCerebral Palsy, DyskineticTrihexyphenidyl Adverse ReactionPharmacogenomic Drug Interaction
Interventions
DRUG

Trihexyphenidyl

6-week dose escalation up to 0.25mg/kg TID, followed by a 9-week maintenance period at this dose

Trial Locations (1)

64108

RECRUITING

Children's Mercy Hospital Kansas City, Kansas City

All Listed Sponsors
collaborator

University of Kansas Medical Center

OTHER

lead

Children's Mercy Hospital Kansas City

OTHER